Discuss the emerging data presented at ASCO 2024 on the phase 1 study of IMC-F106C (brenetafusp), a PRAME x CD3 ImmTAC bispecific protein in post-checkpoint cutaneous melanoma. (Abstract)

1. What was the objective of this study?

2. How was this study designed/what methodology was used?

3. What results were presented?

i. Patient population: N=46

A. Prior therapy: 100% anti-PD1, 88% anti-CTLA4, 25% BRAF/MEK inhibitors

ii. Primary objectives:

A. Safety

B. Selection of recommended dose

iii. Secondary objectives:

A. Efficacy

B. ctDNA response

Please provide your key takeaways from this study. How might a PRAME x CD3 bispecific product impact the management of melanoma in the future?

Related Content

ICYMI: Highlights From AMCP Nexus 2024

December 26th 2024

Article

Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.

ICYMI: Highlights From ASCO 2024

December 21st 2024

Article

Top coverage from the 2024 American Society of Clinical Oncology (ASCO) annual meeting included research topics in non-small cell lung cancer (NSCLC), multiple myeloma, metastatic colorectal cancer (mCRC), and more.

ICYMI: Highlights From SLEEP 2024

December 18th 2024

Article

Check out our top 5 most-viewed pieces of coverage from the 2024 SLEEP meeting.

ICYMI: Highlights From ACTRIMS 2024

December 12th 2024

Article

Read about the diverse array of research presented at this year's meeting, including novel technological advancements and insights into disease progression in multiple sclerosis (MS).